Results of Meeting
Released
Released
Announcement PDF
ASX Announcement
Results of 2026 Annual General Meeting
Sydney, Australia, 6 November 2026: In accordance with ASX Listing Rule 3.13.2 and section
251AA of the Corporations Act 2001 (Cth), the results of the Recce Pharmaceuticals Limited
(ASX:RCE, FSE:R9Q) Annual General Meeting held today at 9:00am (AEDT) are attached.
All resolutions put to the Annual General Meeting were decided by way of poll.
About Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives
designed to address the urgent global health problems of antibiotic-resistant superbugs.
Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives:
RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious
and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their
superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE®
529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce’s anti-infectives have
the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current
challenge facing existing antibiotics.
The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in
clinical development for priority pathogens, recognising Recce’s efforts to combat antimicrobial resistance.
The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic
Incentives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval.
R327 is also included on The Pew Charitable Trusts’ Global New Antibiotics in Development Pipeline as the
sole synthetic polymer and sepsis drug candidate in development.
Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce’s anti-infective
pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.
This announcement has been approved for release by Recce Pharmaceuticals Board.
EWceædc_å@WWdZ^X
EWUUWCYçb]çUWedZUçæc?dV
5^^eçæéW^Wbçæ@WWdZ^X
:bZVçè $*A_fW]TWb&$&*
<^çUU_bVç^UWgZdYcWUdZ_^&)%55_ådYW7_b`_bçdZ_^c5Ud&$$% dYWå_ææ_gZ^XZ^å_b]çdZ_^Zc`b_fZVWVZ^bWæçdZ_^d_bWc_æedZ_^c`edd_]W]TWbcçddYW]WWdZ^X"
5ed_]ZU
éCB6_h)%-' FèV^Wè AFJ&$$%
C%'$$&,,**(çec_b*%$&-*-,)(%(g_bæV
:*%$&,),''$($9YWææ_4çed_]ZU"U_]"çe
56A&+%)&&*$,%(
Cb_hèI_dWcçcçd`b_hèf_dZ^XUæ_cW C_ææEWceædcZåç``æZUçTæW EWceædc
EWc_æedZ_^
8WUZVWVTè
FY_g_å
;ç^VcF_b
C_ææC
:BE 5é5<AFG 56FG5<A
CEBKLF
8<F7E9G<BA
:BE 5é5<AFG 56FG5<A BHG7B@9
F&)$H
5CC?<756?9
%5V_`dZ_^_åEW]e^WbçdZ_^EW`_bd C
,( $,' ('-
*("'-
() *') ,'+
'("-)
(&) )$%
,), &-+
$"**
-% )%( +$-
**"%(
(* ,)( '+'
''",*
(&) )$% ! LWc(a)
&9æWUdZ_^_åFYçbWY_æVWb!A_]Z^çdWV7ç^VZVçdW!@c"
8Zç^ç:_bcèdY
C
*% &$( $*(
()"(+
+& )-% +(+
)'"-'
&&+ ')'
,$% $+)
$"*$
*& *), (%$
(("$&
+- *,( $&(
))"-,
&+' '%( A_d7çbbZWV ^#ç
'EW!WæWUdZ_^_å@c"@ZUYWæW8ZæZiZççc8ZbWUd_b C
++ (&& &()
)+")&
)* ',, &($
(%",-
&%& *+-
,$% $+)
$"*$
,( ++$ ''&
)-")(
)+ *$* ++*
($"(*
&', *($ 7çbbZWV ^#ç
(9æWUdZ_^_åFYçbWY_æVWb!A_]Z^çdWV7ç^VZVçdW!@b"
5]_c@WædiWb
C
(* ((% +'-
'("))
,+ %+% $+&
*(",)
(%$ ')'
,$% $+)
$"*$
(+ )+% $,*
''")$
-( ((, '$-
**")$
)-* ')' A_d7çbbZWV ^#ç
)9æWUdZ_^_åFYçbWY_æVWb!A_]Z^çdWV7ç^VZVçdW!8b"
=ebXW^@ZUYçWæZc
C
(+ '(& ,)+
')"%)
,* )') -)(
*("&)
%(( ')'
,$% $+)
$")-
(, *%% '-'
'("%(
-' +,( $$&
*)",*
&&$ ')' A_d7çbbZWV ^#ç
*EW!WæWUdZ_^_å@b"5æZcdçZb@U>W_eXYçc8ZbWUd_b ! EWc_æedZ_^gZdYVbçg^ ! ^#ç
+9æWUdZ_^_åFYçbWY_æVWb!A_]Z^çdWV7ç^VZVçdW!8b"
Cçeæ@çU?W]ç^
C
*% *(& %+-
()"++
+& &&- *'&
)'"*'
%)% ')'
,$% $+)
$")-
*- $,+ &+'
(,")%
+' ''% %*%
)%"(-
%-+ '%( A_d7çbbZWV ^#ç
,5FK?ZcdZ^XEeæW+"%55``b_fçæ_å:edebW<cceW_å
FWUebZdZWc
C
+) ',+ $&-
))"--
(( *+' ,&%
''"%,
%,$ $-&
%( ),' &-+
%$",'
-* ((& &--
*+"+%
() --' ')+
'&"&-
%,$ $-& A_d7çbbZWV ^#ç
-EçdZåZUçdZ_^_åCbZ_b<cceW_åCæçUW]W^dFYçbWc C
)( **) +,)
(-"$-
(& %$$ $(+
'+",%
&& '*% ,((
%( ),' &-+
%'"%$
+) ++* $-(
*'"*$
(' '*( )((
'*"($
&& '*% ,(( 7çbbZWV ^#ç
Cb_hèI_dWcçcçd`b_hèf_dZ^XUæ_cW C_ææEWceædcZåç``æZUçTæW EWceædc
EWc_æedZ_^
8WUZVWVTè
FY_g_å
;ç^VcF_b
C_ææC
:BE 5é5<AFG 56FG5<A
CEBKLF
8<F7E9G<BA
:BE 5é5<AFG 56FG5<A BHG7B@9
F&)$H
5CC?<756?9
%$5V_`dZ_^_å9]`æ_èWW<^UW^dZfWCæç^ C
,* +*$ -)+
*)"&*
() '&' ((&
'("$-
'&$ -,$
,), &-+
$"*)
-' *+% &**
**"+-
(* )*+ -'-
''"&%
,%) -,$ 7çbbZWV ^#ç
%%F`ZææEWc_æedZ_^7_^VZdZ_^çæEWc_æedZ_^ C
(+ **' )&,
'*"+)
,% %&' -,&
*&")(
% &-% $**
-&( (-,
$"+%
(, -,% -%*
')"+-
,+ ,-$ *($
*("&%
% -&& $&+ A_d7çbbZWV ^#ç
Note: (a) As more than 25% of the votes cast on Resolution 1 were against the adoption of the Remuneration Report, this constitutes a ‘second strike’ under section 250U of the Corporations Act 2001 (Cth), however Resolution 11, the spill resolution, was not passed.
Share your feedback
Discover